Eli Lilly and Company

Shun Li

Bruce H Frank

Michael Rosario DeFelippis

Michael Allen Dobbins

Dawn Marie Rebhun

John Michael Beals

Christopher Carl Frye

Wolfgang Glaesner

Radmila Micanovic

Beth Ann Strifler

Lianshan Zhang

Radhakrishnan Rathnachalam

Jing Shang

Ryan John Hansen

Gordon Butler Cutler, Jr

Brandon Doyle

Shahriar Shirani

Gordon Butler Cutler

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.

PEGylated insulin lispro compounds

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Muteins of fibroblast growth factor 21

The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

Stable insulin formulations

Growing community of inventors

Carmel, IN, United States of America

Shun Li